Please assess the completion status of the following clinical trial:

Trial Title: Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent from legally acceptable guardian~* PPHN or hypoxemic respiratory failure associated with:~  * Idiopathic PPHN~ * Meconium aspiration syndrome~ * Respiratory distress syndrome~ * Sepsis~ * Pneumonia~* Greater than or equal to 35 weeks gestation~* Age at enrollment less than 72 hours~* Moderate hypoxemic respiratory failure, with 12\<OI\<35 (oxygenation index, calculated as FiO2 \* mean airway pressure \* 100 / postductal PaO2)~* Absence of structural heart disease (except patent ductus arteriosus, atrial septal defect \<1cm, or muscular ventricular septal defect \< 2mm)~* Absence of lethal congenital anomaly~* Not participating in another concurrent experimental study~Exclusion Criteria:~* Prior or immediate need for iNO or ECMO~* Profound hypoxemia: qualifying PaO2 \<30 mmHg, from a blood gas drawn within 30 minutes of starting study drug infusion.~* Hypotension: Mean arterial pressure \<35 mmHg~* Congenital heart disease, except patent ductus arteriosus, atrial septal defect \<1cm, or muscular ventricular septal defect \<2mm~* Congenital diaphragmatic hernia or lung hypoplasia syndromes, diagnosed on the basis of prolonged oligohydramnios~* Active seizures~* Apgar score of \<3 at 5 minutes~* Bleeding diathesis~* Receipt of any other experimental drug or device~* Receipt of any prohibited concurrent medication:~  * Potent cytochrome P450 3A4 inhibitors (e.g., erythromycin, ketoconazole, itraconazole and protease inhibitors)~ * Endothelin antagonists (e.g. Tracleer/bosentan)~ * Intravenous nitrates or nitric oxide donors~* Known hereditary degenerative retinal disorders such as retinitis pigmentosa.~* In the opinion of the investigator, a subject who is not likely to complete the study or would be considered inappropriate for the study, for any reason.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Study Arms:
- Intravenous Sildenafil (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): 0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).